<DOC>
	<DOCNO>NCT02007278</DOCNO>
	<brief_summary>The purpose study compare effect fix dose combination vildagliptin plus metformin versus combination therapy glimepiride plus metformin glycemic variability patient type 2 diabetes achieve adequate control disease prior treatment metformin monotherapy optimal dos .</brief_summary>
	<brief_title>Glycemic Excursions Type 2 Diabetic Patients With Vildagliptin Metformin Versus Vildagliptin Glimepiride</brief_title>
	<detailed_description />
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>HbA1c 8 % 10.5 % stable metformin dose ( &gt; 1500 mg/day ) , four week prior visit 1 Use antidiabetic oral therapy last 3 month ( sulphonylurea , glitazones , GLP1 analogues , DPP4 inhibitor ) , except metformin Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>diabetes</keyword>
	<keyword>hypoglycemia</keyword>
	<keyword>glycemic variability</keyword>
	<keyword>vildagliptin</keyword>
	<keyword>glimepiride</keyword>
</DOC>